These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 18284457)

  • 61. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
    Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
    Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [The International Prognostic Scoring System for primary myelodysplastic syndrome].
    Sisková M; Dohnalová A; Neuwirtová R; Pĕnicková J; Karban J; Cmunt E
    Sb Lek; 2002; 103(3):333-8. PubMed ID: 12688177
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
    Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
    Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
    Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
    Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival.
    Breccia M; Latagliata R; Carmosino I; Gentilini F; D'Elia GM; Levi A; Natalino F; Frustaci A; De Cuia MR; Alimena G
    Acta Haematol; 2007; 117(4):221-5. PubMed ID: 17259693
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The myelodysplastic syndrome].
    Iványi JL; Jancsik V; Kiss A; Mahunka I; Telek B; Rák K
    Orv Hetil; 1991 Jun; 132(22):1179-84. PubMed ID: 2067828
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Giardini I; Rocca B; Zappatore R; Dambruoso I; Calvello C; Caresana M; Lazzarino M
    Ann Hematol; 2010 Jun; 89(6):545-51. PubMed ID: 20217086
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
    De Roos AJ; Deeg HJ; Davis S
    Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study.
    Giannouli S; Voulgarelis M; Zintzaras E; Tzioufas AG; Moutsopoulos HM
    Rheumatology (Oxford); 2004 May; 43(5):626-32. PubMed ID: 14983106
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
    Greenberg PL; Sanz GF; Sanz MA
    Forum (Genova); 1999; 9(1):17-31. PubMed ID: 10101208
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical significance of regulatory T cells in patients with myelodysplastic syndrome.
    Hamdi W; Ogawara H; Handa H; Tsukamoto N; Nojima Y; Murakami H
    Eur J Haematol; 2009 Mar; 82(3):201-7. PubMed ID: 19018862
    [TBL] [Abstract][Full Text] [Related]  

  • 74. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients.
    Maschek H; Georgii A; Kaloutsi V; Werner M; Bandecar K; Kressel MG; Choritz H; Freund M; Hufnagl D
    Eur J Haematol; 1992 Apr; 48(4):208-14. PubMed ID: 1592101
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.
    Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM
    Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866
    [TBL] [Abstract][Full Text] [Related]  

  • 77. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.
    Breccia M; Mancini M; Nanni M; D'Elia GM; Carmosino I; Latagliata R; Sarlo C; Mandelli F; Alimena G
    Leuk Res; 2005 Jan; 29(1):33-9. PubMed ID: 15541472
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Myelodysplastic syndrome. A clinical and pathological analysis of 88 patients.
    Nair R; Iyer RS; Nair CN; Kurkure PA; Pai SK; Saikia TK; Nadkarni KS; Pai VR; Gopal R; Advani SH
    Indian J Cancer; 1993 Dec; 30(4):169-75. PubMed ID: 8206499
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.